Cover Image
市場調查報告書

精密醫療的全球市場分析、預測:進入經營者、技術、對象疾病、專利、研發產品線、產品製圖、市場佔有率、競爭分析

Global Precision Medicine Market - Analysis and Forecast 2017-2026: Focus on Ecosystem Player, Technology, Therapeutic Applications, Patent Landscape, Country Analysis, R&D Pipeline, Product Mapping, Market Share Analysis and Competitive Insights

出版商 BIS Research Private Limited 商品編碼 345248
出版日期 內容資訊 英文 580 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
精密醫療的全球市場分析、預測:進入經營者、技術、對象疾病、專利、研發產品線、產品製圖、市場佔有率、競爭分析 Global Precision Medicine Market - Analysis and Forecast 2017-2026: Focus on Ecosystem Player, Technology, Therapeutic Applications, Patent Landscape, Country Analysis, R&D Pipeline, Product Mapping, Market Share Analysis and Competitive Insights
出版日期: 2017年12月15日 內容資訊: 英文 580 Pages
簡介

本報告提供全球精密醫療的市場調查,市場定義和概要,技術的發展過程,市場成長的各種影響因素分析,相關法律、當局、相關團體等,各進入經營者區分、技術區分、疾病區分、地區的主要趨勢及市場規模的變化與預測,主要企業簡介等彙整。

摘要整理

第1章 報告範圍、調查手法

第2章 市場概要

  • 簡介
  • 精密醫療的方法
  • 技術的進步
  • 關心的領域
  • 舉措&計劃

第3章 市場動態

  • 概要
  • 影響分析
  • 推動成長因素
  • 阻礙成長要素
  • 市場機會

第4章 競爭分析

  • 主要的發展、策略
  • 競爭環境
  • 市場佔有率分析
  • 產業的魅力
  • 供應鏈分析

第5章 產業分析

  • 專利分析
  • 法律上的必要條件、各種法規
  • FDA所扮演的角色
  • 法規當局
  • 聯盟
  • 聯盟、協會等

第6章 市場分析:各參與企業

  • 概要
  • 醫藥品、生物科技企業
    • 作用
    • 藥物開發過程
    • 藥物範例
    • 成長推動因素與課題
    • 近幾年主要的發展
  • 診斷相關經營者、臨床檢驗實驗室
    • 成長推動因素與課題
    • 對相關利益者來說的診斷檢驗的優點
    • 近幾年主要的發展
  • 醫療保健IT/巨量資料相關經營者
    • 巨量資料的優點
    • 成長推動因素與課題
    • 精密醫療中巨量資料的重要性
    • 近幾年主要的發展

第7章 市場分析:各技術

  • 概要
  • 生物標記檢驗的重要性
  • 搭配診斷
    • 藥物、搭配診劃分發過程
    • 成長推動因素與課題
    • 近幾年主要的發展
  • 生物資訊學
  • 巨量資料分析
  • 遺傳基因定序
    • 精密醫療的定序技術
    • 成長推動因素與課題
    • 遺傳基因定序的各種用途
    • 近幾年主要的發展
  • 醫藥基因學
    • 醫藥基因學檢驗臨床用途
    • 醫藥基因學的FDA所扮演的角色
  • 分子診斷
  • 其他
    • 消費者基因學
    • 3D列印
    • 義肢市場
    • 人組織市場

第8章 市場分析:各疾病種類

  • 概要
  • 癌症
  • 心臟血管
  • 中樞神經
  • 感染疾病
  • 免疫
  • 其他
  • 近幾年主要的發展

第9章 市場分析:各地區

  • 概要
  • 重要考察
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第10章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BH002B

The global precision medicine market was dominated by the oncology segment in 2016. The oncology market is expected to grow with a CAGR of 10.4% from 2017 to 2026. The rise in the number of cancer cases has significantly increased the global economic burden and is estimated to be approximately $4 trillion in 2025.

Various advancements in the life sciences industry have paved the way for development of several precision medicine solutions. It is one of the most modernized trends in the healthcare industry that has projected tremendous level of progress in the last few years. The completion of the Human Genome project in 2003 and the precision medicine initiative in 2015 provided a path of opportunity to introduce new scientific, medical, and business models in the precision medicine market. The sole idea behind the development of precision medicine solution is to provide targeted therapies to population based on their genomic structure. Therefore, the application of ‘omics' (genomics, proteomics, transcriptomics) analysis is widely used in this market. The precision medicine market is a multibillion market which consists of innumerable companies involved in the research and development, manufacturing and commercialization of several novel drugs and diagnostic kits to boost the Precision Medicine workflow.

Currently, the precision medicine market is gaining preference among the masses due to the growth of personal healthcare devices and integration of smart technologies in the healthcare system. In addition, increasing collaborations and partnerships between various ecosystem players are aiding in the robust growth of the precision medicine market. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), government support and regulations, which consequently, have created a demand for the precision medicine solutions. Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The primary aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases, among others.

The purpose of this study is to gain a holistic view of the precision medicine market in terms of various influencing factors, such as recent trends, technological advancements, and role of various key stakeholders in the market. The scope of this report constitutes of an in-depth study of the global precision medicine market. The market has been segmented into ‘ecosystem players' ‘technology', ‘therapeutic applications' and ‘region'. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the crucial parameters that must be taken into consideration before entering into the market.

The research report aims at answering various aspects of the global precision medicine market with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key ecosystem players and key strategies & developments taking place in this market.

The research study considers the market share analysis for a comprehensive understanding of the global precision medicine market and assesses the factors governing the same. The supply chain analysis, Porter's Five Force analysis, patent landscape, detailed product mapping and R&D analysis have been included in the report.

The market by region has been further sub-segmented in countries and in each sub-segments, key market trends, list of key players, and recent developments were listed.

The answers to the following key questions can be derived from this report:

  • How did the precision medicine market evolve and what is its scope in the future?
  • What is the approach followed in the development of precision medicine solutions?
  • What are the key areas of interest for the development of precision medicine?
  • What are the major market drivers, challenges and opportunities in the global precision medicine market?
  • What are the key initiatives and programs launched in the precision medicine market?
  • What are the key developmental strategies which are being implemented by the key players to stand out in this market? Among these strategies, which strategy is currently dominating the market?
  • What are the precision medicine solutions provided by the key companies? What are the key products in pipeline?
  • Who are the key players holding significant number of patents in the precision medicine market?
  • How is the Porter's Five Forces affecting the industry attractiveness in the precision medicine market?
  • What is the role of different stakeholders in value chain for the precision medicine market?
  • What is the total addressable market (TAM), segmental addressable market (SAM) and the potential market opportunity of the global precision medicine market?
  • What is the market share of different leading segments and sub-segments of the market for the years 2017 and 2026?
  • How each of the segments of the global precision medicine market will grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2026?
  • Who are the key players dominating the global precision medicine market and what are their respective shares in the market?
  • Who are the key players dominating the precision medicine market, in different segments namely the ecosystem players, technologies, and therapeutic applications?
  • What are the influencing factors that may affect the market share of the key players?
  • Who are the leading ecosystem players in the precision medicine market and what is their contribution to the market? What are the key drivers and challenges in each ecosystem player?
  • How the market has been segmented on the basis of technology? Which technology is leading and what is its share in the market? What are the key drivers and challenges in each technology?
  • How the market has been segmented on the basis of therapeutic application? Which therapeutic application is leading and what is its share in the market? What are the key drivers and challenges in each therapeutic application?
  • Which geographical location will contribute to the highest sales of precision medicine solutions and how regions have been further segmented into countries?
  • Who are the key players dominating the precision medicine market, in different regions namely North America, Europe, and Asia Pacific? What are the key drivers and challenges in each of the geographical regions?
  • How many countries are covered in each geographical region? Which country is currently dominating the precision medicine market?
  • What are the key strengths, weaknesses, opportunities, and threat for each of the key players in the precision medicine market?

The key players which have been contributing significantly to the precision medicine market include Abbott Laboratories, Almac Group, Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, ASURAGEN, INC., bioMerieux SA, BRISTOL-MYERS SQUIBB COMPANY, CETICS Healthcare Technologies GmbH, Eli-Lilly and Company, F. Hoffmann-La Roche AG, GE Healthcare, Gilead Sciences, Inc., GlaxoSmithKline, IBM Corporation, Illumina, Inc., Intomics A/S, JOHNSON & JOHNSON, Laboratory Corporation of America, Merck KGaA, Novartis AG, Pfizer, Inc., QIAGEN, Quest Diagnostics, Randox Laboratories, SANOFI, Teva Pharmaceuticals Limited, and Thermo Fisher Scientific, among others.

Table of Contents

Executive Summary

1. Report Scope & Methodlogy

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Primary Research
    • 1.3.2. Secondary Research
    • 1.3.3. Data Triangulation
    • 1.3.4. Key Data Points from Primary Sources
    • 1.3.5. Key Data Points from Secondary Sources
    • 1.3.6. Top-Down Approach (Segmental Analysis)
    • 1.3.7. Bottom-Up Approach (Segmental Analysis)
  • 1.5. Assumptions and Limitations

2. Market Overview

  • 2.1. Introduction
  • 2.1. Precision Medicine Approach
  • 2.1. Evolution of Precision Medicine Technology
  • 2.1. Precision Medicine: Areas of Interest
  • 2.1. Initiatives and Programs

3. Market Dynamics

  • 3.1. Overview
  • 3.2. Impact Analysis
  • 3.3. Drivers
  • 3.4. Restraints
  • 3.5. Opportunities

4. Competitive Insights

  • 4.1. Share of Key Development and Strategies
  • 4.2. Competitive Landscape of Some of the Key Players
  • 4.3. Market Share Analysis
  • 4.4. Industry Attractiveness
    • 4.3.1. Definition of Suppliers and Buyers in Precision Medicine Market
    • 4.3.2. Bargaining Power of Suppliers
    • 4.3.3. Bargaining Power of Buyers
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Threat of Substitute Products
    • 4.3.6. Intensity of Competitive Rivalry
  • 4.5. Supply Chain Analysis

5. Industry Insights

  • 5.1. Patent Analysis
  • 5.2. Legal Requirements and Regulations
  • 5.3. Role of FDA in Advancing Precision Medicine
  • 5.4. Regulatory Bodies in Precision Medicine
  • 5.5. Consortiums in the Precision Medicine Market
  • 5.6. Alliance/Associations in the Precision medicine Market

6. Global Precision Medicine Market, by Ecosystem Players

  • 6.1. Overview
  • 6.2. Pharmaceutical and Biotechnology Companies
    • 6.2.1. Role of Pharmaceutical and Biotechnology Companies
    • 6.2.2. Drug Development Process
    • 6.2.3. Examples of Some Precision Medicine Drugs
    • 6.2.4. Pharmaceutical and Biotechnology Companies: Drivers and challenges
    • 6.2.5. Pharmaceutical and Biotechnology Companies: Recent Key Developments
  • 6.3. Diagnostic Companies and Clinical Research Laboratories
    • 6.3.1. Pharmaceutical and Biotechnology Companies: Drivers and challenges
    • 6.3.2. Diagnostic Tests Benefits for Stakeholders
    • 6.3.3. Pharmaceutical and Biotechnology Companies: Recent Key Developments
  • 6.4. Healthcare IT/ Big Data Companies
    • 6.4.1. Benefits of Big Data
    • 6.4.2. Pharmaceutical and Biotechnology Companies: Drivers and challenges
    • 6.4.3. Basic Ingredients Provide by Big Data for Precision Medicine
    • 6.4.4. Big Data Companies: Recent Key Developments

7. Global Precision Medicine Market, by Technology

  • 7.1. Overview
  • 7.2. Role of Biomarker Based Test
  • 7.3. Companion Diagnostics
    • 7.3.1. Drug and Companion Diagnostics Development Process
    • 7.3.2. Companion Diagnostics:Drivers and challenges
    • 7.3.3. Companion Diagnostics: Recent Key Developments
  • 7.4. Bioinformatics
  • 7.5. Big Data Analytics
  • 7.6. Gene Sequencing
    • 7.6.1. Sequencing Technologies in Precision Medicine
    • 7.6.2. Gene Sequencing:Drivers and challenges
    • 7.6.3. Applications of Gene Sequencing
    • 7.6.4. Gene Sequencing: Recent Key Developments
  • 7.7. Pharmacogenomics
    • 7.7.1. Clinical Applications of Pharmacogenomics Testing
    • 7.7.2. Role of FDA in Pharmacogenomics
  • 7.8. Molecular Diagnostics
  • 7.9. Others
    • 7.9.1. Consumer Genomics
    • 7.9.2. 3D Printing
    • 7.9.3. Prosthetic Market
    • 7.9.4. Human tissues Market

8. Global Precision Medicine Market, by Therapeutic Application

  • 8.1. Overview
  • 8.2. Oncology
    • 8.2.1. Types of Cancer
    • 8.2.2. Government Initiatives
    • 8.2.3. Oncology:Drivers and challenges
    • 8.2.4. Oncology: Recent Key Developments
  • 8.3. Cardiovascular
  • 8.4. Central Nervous System
  • 8.5. Infectious Diseases
  • 8.6. Immunology
  • 8.7. Others
  • 8.8. Recent Key Developments

9. Global Precision Medicine Market, by Region

  • 9.1. Overview
  • 9.2. Key Insights
  • 9.3. North America
    • 9.3.1. Market Scope
    • 9.3.2. North America: Market Insights and Statistics
    • 9.3.3. North America: by Country
    • 9.3.4. North America: by Ecosystem Players
    • 9.3.5. North America: by Technology
    • 9.3.6. North America: by Therapeutic Applications
    • 9.3.7. North America: Market Dynamics
    • 9.3.8. Key Regulatory Bodies and Associations
    • 9.3.9. The U.S.
      • 9.3.9.1. The U.S.: by Ecosystem Players
      • 9.3.9.2. The U.S.: by Technology
      • 9.3.9.3. The U.S.: by Therapeutic Applications
    • 9.3.10. Canada
    • 9.3.7. Key Market Players in North America
    • 9.3.8. North America: Recent Key Developments
  • 9.4. Europe
    • 9.4.1. Market Scope
    • 9.4.2. Europe: Market Insights and Statistics
    • 9.4.3. Europe: by Country
    • 9.4.4. Europe: by Ecosystem Players
    • 9.4.5. Europe: by Technology
    • 9.4.6. Europe: by Therapeutic Applications
    • 9.4.7. Europe: Market Dynamics
    • 9.4.8. Germany
    • 9.4.9. The U.K.
    • 9.4.10. France
    • 9.4.11. Italy
    • 9.4.12. Spain
    • 9.4.13. Rest of Europe
    • 9.4.14. Key Market Players in Europe
    • 9.4.15. Europe: Recent Key Developments
  • 9.5. Asia Pacific
    • 9.5.1. Market Scope
    • 9.5.2. Asia Pacific: Market Insights and Statistics
    • 9.5.3. Asia Pacific: by Country
    • 9.5.4. Asia Pacific: by Ecosystem Players
    • 9.5.5. Asia Pacific: by Technology
    • 9.5.6. Asia Pacific: by Therapeutic Applications
    • 9.5.7. Asia Pacific: Market Dynamics
    • 9.5.8. China
    • 9.5.9. Japan
    • 9.5.10. India
    • 9.5.11. Australia
    • 9.5.12. Rest of Asia Pacific
    • 9.5.13. Key Market Players in Asia Pacific
  • 9.6. Rest of the World
    • 9.6.1. Rest of the World: Market Insights and Statistics
    • 9.6.2. Rest of the World: by Ecosystem Players
    • 9.6.3. Rest of the World by Technology
    • 9.6.4. Rest of the World: by Therapeutic Applications
    • 9.6.5. Asia Pacific: Market Dynamics
    • 9.6.6. Middle East
    • 9.6.7. South America
    • 9.6.8. Africa
    • 9.6.9. Rest of the World: Recent Key Developments

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Overview
    • 10.1.2. Product Portfolio
    • 10.1.3. Financials
      • 10.1.3.1. Finacial Summary
    • 10.1.4. SWOT Analysis
  • 10.2. Almac Group
    • 10.2.1. Overview
    • 10.2.2. Product Portfolio
    • 10.2.3. Financials
      • 10.2.3.1. Finacial Summary
    • 10.2.4. SWOT Analysis
  • 10.3. Amgen, Inc
    • 10.3.1. Overview
    • 10.3.2. Product Portfolio
    • 10.3.3. Financials
      • 10.3.3.1. Finacial Summary
    • 10.3.4. SWOT Analysis
  • 10.4. ANGLE plc
    • 10.4.1. Overview
    • 10.4.2. Financials
      • 10.4.2.1. Finacial Summary
    • 10.4.3. SWOT Analysis
  • 10.5. Astellas Pharma, Inc
    • 10.5.1. Overview
    • 10.5.2. Product Portfolio
    • 10.5.3. Financials
      • 10.5.3.1. Finacial Summary
    • 10.5.4. SWOT Analysis
  • 10.6. AstraZeneca PLC
    • 10.6.1. Overview
    • 10.6.2. Product Portfolio
    • 10.6.3. Financials
      • 10.6.3.1. Finacial Summary
    • 10.6.4. SWOT Analysis
  • 10.7. ASURAGEN, INC.
    • 10.7.1. Overview
    • 10.7.2. Product Portfolio
    • 10.7.3. Corporate Summary
    • 10.7.4. SWOT Analysis
  • 10.8. Bio-Rad Laboratories, Inc.
    • 10.8.1. Overview
    • 10.8.2. Product Portfolio
    • 10.8.3. Financials
      • 10.8.3.1. Finacial Summary
    • 10.8.4. SWOT Analysis
  • 10.9. bioMérieux SA
    • 10.9.1. Overview
    • 10.9.2. Financials
      • 10.9.2.1. Finacial Summary
    • 10.9.3. SWOT Analysis
  • 10.10. BRISTOL-MYERS SQUIBB COMPANY
    • 10.10.1. Overview
    • 10.10.2. Product Portfolio
    • 10.10.3. Financials
      • 10.10.3.1. Finacial Summary
    • 10.10.4. SWOT Analysis
  • 10.11. CETICS Healthcare Technologies GmbH
    • 10.11.1. Overview
    • 10.11.2. Product Portfolio
    • 10.11.3. Corporate Summary
    • 10.11.4. SWOT Analysis
  • 10.12. Danaher Corporation
    • 10.12.1. Overview
    • 10.12.2. Product Portfolio
    • 10.12.3. Financials
      • 10.12.3.1. Finacial Summary
    • 10.12.4. SWOT Analysis
  • 10.13. Eli Lilly and Company
    • 10.13.1. Overview
    • 10.13.2. Product Portfolio
    • 10.13.3. Financials
      • 10.13.3.1. Finacial Summary
    • 10.13.4. SWOT Analysis
  • 10.14. Epic Sciences, Inc.
    • 10.14.1. Overview
    • 10.14.2. Corporate Summary
    • 10.14.3. SWOT Analysis
  • 10.15. F.Hoffmann-La Roche AG
    • 10.15.1. Overview
    • 10.15.2. Product Portfolio
    • 10.15.3. Financials
      • 10.15.3.1. Finacial Summary
    • 10.15.4. SWOT Analysis
  • 10.16. GE Corporation
    • 10.16.1. Overview
    • 10.16.2. Product Portfolio
    • 10.16.3. Financials
      • 10.16.3.1. Finacial Summary
    • 10.16.4. SWOT Analysis
  • 10.17. Gilead Sciences, Inc.
    • 10.17.1. Overview
    • 10.17.2. Product Portfolio
    • 10.17.3. Financials
      • 10.17.3.1. Finacial Summary
    • 10.17.4. SWOT Analysis
  • 10.18. GlaxoSmithKline Plc
    • 10.18.1. Overview
    • 10.18.2. Product Portfolio
    • 10.18.3. Financials
      • 10.18.3.1. Finacial Summary
    • 10.18.4. SWOT Analysis
  • 10.19. IBM Corporation
    • 10.19.1. Overview
    • 10.19.2. Product Portfolio
    • 10.19.3. Financials
      • 10.19.3.1. Finacial Summary
    • 10.19.4. SWOT Analysis
  • 10.20. Illumina, Inc.
    • 10.20.1. Overview
    • 10.20.2. Product Portfolio
    • 10.20.3. Financials
      • 10.20.3.1. Finacial Summary
    • 10.20.4. SWOT Analysis
  • 10.21. Intomics A/S
    • 10.21.1. Overview
    • 10.21.2. Product Portfolio
    • 10.21.3. Corporate Summary
    • 10.21.4. SWOT Analysis
  • 10.22. JOHNSON & JOHNSON
    • 10.22.1. Overview
    • 10.22.2. Product Portfolio
    • 10.22.3. Financials
      • 10.22.3.1. Finacial Summary
    • 10.22.4. SWOT Analysis
  • 10.23. Laboratory Corporation of America
    • 10.23.1. Overview
    • 10.23.2. Product Portfolio
    • 10.23.3. Financials
      • 10.23.3.1. Finacial Summary
    • 10.23.4. SWOT Analysis
  • 10.24. MDX Health, Inc.
    • 10.24.1. Overview
    • 10.24.2. Financials
      • 10.24.2.1. Finacial Summary
    • 10.24.3. SWOT Analysis
  • 10.25. Menarini Silicon Biosystems, Inc.
    • 10.25.1. Overview
    • 10.25.2. Product Portfolio
    • 10.25.3. Corporate Summary
    • 10.25.4. SWOT Analysis
  • 10.26. KGaA
    • 10.26.1. Overview
    • 10.26.2. Financials
      • 10.26.2.1. Finacial Summary
    • 10.26.3. SWOT Analysis
  • 10.27. Myriad Genetics, Inc.
    • 10.27.1. Overview
    • 10.27.2. Product Portfolio
    • 10.27.3. Financials
      • 10.27.3.1. Finacial Summary
    • 10.27.4. SWOT Analysis
  • 10.28. Novartis AG
    • 10.28.1. Overview
    • 10.28.2. Product Portfolio
    • 10.28.3. Financials
      • 10.28.3.1. Finacial Summary
    • 10.28.4. SWOT Analysis
  • 10.29. Oracle
    • 10.29.1. Overview
    • 10.29.2. Product Portfolio
    • 10.29.3. Financials
      • 10.29.3.1. Finacial Summary
    • 10.29.4. SWOT Analysis
  • 10.30. Pacific Biosciences of California, Inc.
    • 10.30.1. Overview
    • 10.30.2. Corporate Summary
    • 10.30.3. Product Portfolio
    • 10.30.4. Financials
      • 10.30.4.1. Finacial Summary
    • 10.30.5. SWOT Analysis
  • 10.31. Partek, Inc.
    • 10.31.1. Overview
    • 10.31.2. Corporate Summary
    • 10.31.3. Product Portfolio
    • 10.31.4. SWOT Analysis
  • 10.32. Pfizer
    • 10.32.1. Overview
    • 10.32.2. Product Portfolio
    • 10.32.3. Financials
      • 10.32.3.1. Finacial Summary
    • 10.32.4. SWOT Analysis
  • 10.33. QIAGEN
    • 10.33.1. Overview
    • 10.33.2. Product Portfolio
    • 10.33.3. Financials
      • 10.33.3.1. Finacial Summary
    • 10.34.4. SWOT Analysis
  • 10.34. Quest Diagnostics
    • 10.34.1. Overview
    • 10.34.2. Product Portfolio
    • 10.34.3. Financials
      • 10.34.3.1. Finacial Summary
    • 10.34.4. SWOT Analysis
  • 10.35. Randox Laboratories
    • 10.35.1. Overview
    • 10.35.2. Product Portfolio
    • 10.35.3. Corporate Summary
    • 10.35.4. SWOT Analysis
  • 10.36. SANOFI
    • 10.36.1. Overview
    • 10.36.2. Product Portfolio
    • 10.36.3. Financials
      • 10.36.3.1. Finacial Summary
    • 10.36.4. SWOT Analysis
  • 10.37. Sysmex Corporation
    • 10.37.1. Overview
    • 10.37.2. Product Portfolio
    • 10.37.3. Financials
      • 10.37.3.1. Finacial Summary
    • 10.37.4. SWOT Analysis
  • 10.38. Teva Pharmaceuticals Industries Limited.
    • 10.38.1. Overview
    • 10.38.2. Product Portfolio
    • 10.38.3. Financials
      • 10.38.3.1. Finacial Summary
    • 10.38.4. SWOT Analysis
  • 10.39. Thermo Fisher Scientific
    • 10.39.1. Overview
    • 10.39.2. Product Portfolio
    • 10.39.3. Financials
      • 10.39.3.1. Finacial Summary
    • 10.39.4. SWOT Analysis
  • 10.40. TROVAGENE, INC.
    • 10.40.1. Overview
    • 10.40.2. Product Portfolio
    • 10.40.3. Financials
      • 10.40.3.1. Finacial Summary
    • 10.40.4. SWOT Analysis
  • 10.41. Snapshot of Some Key Companies
    • 10.41.1. AB-BIOTICS SA
    • 10.41.2. ARIEL Precision Medicine, Inc.
    • 10.41.3. CARIS LIFE Science
    • 10.41.4. Continuous Precision Medicine
    • 10.41.5. GUARDANT HEALTH, INC
    • 10.41.6. INNVENTIS
    • 10.41.7. Intel Corporation
    • 10.41.8. Mapmygenome
    • 10.41.9. New Medicine Partners
    • 10.41.10. Pacific Edge Diagnostics USA LIMITED
    • 10.41.11. PRECISION FOR MEDICINE
    • 10.41.12. Precision Medicine Alliance
    • 10.41.13. Takeda Pharmaceuticals Company Limited

List of Tables

  • 1. Global Pharma & Biotech Companies Precision Medicine Market, by Therapeutic Application, ($Billion)
  • 2. Example of Some Precision Medicine Drugs
  • 3. Biotechnology and Pharmaceutical Companies- Recent Key Developments
  • 4. Global Diagnostic Tool Companies Precision Medicine Market, by Therapeutic Application, ($Billion)
  • 5. Diagnostic Test Companies- Recent Key Developments
  • 6. Global Healthcare IT/ Big Data Companies Precision Medicine Market, by Therapeutic Application, ($Billion)
  • 7. Service Providers- Recent Developments
  • 8. Global Precision Medicine Market Value, by Technology Types ($Billion)
  • 9. List of Biobanking Initiatives Across Selected OECD Countries
  • 10. Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
  • 11. Global Precision Medicine Market Value, by Region ($Billion)
  • 12. Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
  • 13. Global Precision Medicine Market Value, by Region ($Billion)
  • 14. Next Generation Sequencing- Recent Key Developments
  • 15. List of Biobanks
  • 16. Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
  • 17. Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
  • 18. Companion Diagnostics- Recent Key Developments
  • 19. List of FDA Approved Companion diagnostics
  • 20. Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
  • 21. List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling
  • 22. Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
  • 23. List of Few Human Genetic Tests Approved by FDA
  • 24. List of Few Microbial Tests Approved by FDA
  • 25. Others Molecular Diagnostics : List of Human Genetic Tests
  • 26. Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
  • 27. Global Precision Medicine Market Value, by Technology ($Billion)
  • 28. Cancer Precision Medicine Drugs and Indications
  • 29. Oncology- Recent Developments
  • 30. Global Precision Medicine Market Value, by Technology ($Billion)
  • 31. Cardiovascular Precision Medicine Drugs/Tests/ and Indications
  • 32. Global Precision Medicine Market Value, by Technology ($Billion)
  • 33. Central Nervous System Precision Medicine Drugs and Indications
  • 34. Global Precision Medicine Market Value, by Technology ($Billion)
  • 35. Infectious Diseases Precision Medicine Drugs and Indications
  • 36. Global Precision Medicine Market Value, by Technology ($Billion)
  • 37. Global Precision Medicine Market Value, by Technology ($Billion)
  • 38. Other Diseases: Examples of Some Drugs
  • 39. Recent Key Developments
  • 40. North America Precision Medicine Market, by Technology ($Billion)
  • 41. North America Precision Medicine Market, by Therapeutic Application ($Billion)
  • 42. Key Market Players in North America
  • 43. North American Pharmacogenomics Market Recent Key Developments
  • 44. Europe Precision Medicine Market, by Technology ($Billion)
  • 45. Europe Precision Medicine Market, by Therapeutic Application ($Billion)
  • 46. Key Market Players in Europe
  • 47. Europe: Recent Key Developments
  • 48. Asia Pacific (APAC) Precision Medicine Market, by Technology ($Billion)
  • 49. Asia Pacific (APAC) Precision Medicine Market, by Therapeutic Applications ($Billion)
  • 50. Key Market Players in Asia Pacific
  • 51. Rest of the World (RoW) Precision Medicine Market, by Technology ($Billion)
  • 52. Rest of the World (RoW) Precision Medicine Market, by Therapeutic Application ($Billion)
  • 53. Recent Key Developments

List of Figures

  • 1. Ecosystem Players in Precision Medicine
  • 2. Global Precision Medicine Market Value, by Ecosystem Players ($Billion)
  • 3. Global Pharma & Biotech Companies Precision Medicine Market Value, by Region ($Billion)
  • 4. Role Of Pharmaceuticals And Biotech Companies
  • 5. Drug Development Process
  • 6. Pharmaceutical Companies- Drivers and Challenges
  • 7. Global Diagnostic Tool Companies Precision Medicine Market Value, by Region ($Billion)
  • 8. Diagnostic Companies: Drivers and Challenges
  • 9. Diagnostic Tests Benefits for Stakeholders
  • 10. Global Healthcare IT / Big Data Companies Precision Medicine Market Value, by Region ($Billion)
  • 11. Three Data Drivers of the U.S. Precision Medicine Market
  • 12. Benefits of Big Data
  • 13. Big Data Companies: Drivers and Challenges
  • 14. Transformation of Medicine
  • 15. Basic Ingredients Provided By Big Data for Precision Medicine
  • 16. Key Players
  • 17. Technologies in Precision Medicine
  • 18. Functions of Biomarkers
  • 19. Biomarker Services
  • 20. Biomarkers-List of Biobanks
  • 21. Biomarker Market Dynamics
  • 22. Biomarkers-Recent Key Developments
  • 23. Sequencing Technologies in Pharmacogenomics
  • 24. Next Generation Sequencing: Drivers and Challenges
  • 25. Sequencing Applications
  • 26. Global Precision Medicine Market Value, by Region ($Billion)
  • 27. Global Precision Medicine Market Value, by Region ($Billion)
  • 28. Drug And Companion Diagnostics Development Process
  • 29. Companion Diagnostics: Market Dynamics
  • 30. Global Precision Medicine Market Value, by Region ($Billion)
  • 31. Clinical Applications of Pharmacogenomics Testing
  • 32. Mechanism of Action
  • 33. Role of FDA in Pharmacogenomics
  • 34. Global Precision Medicine Market Value, by Region ($Billion)
  • 35. Types of Molecular Diagnostics Tests
  • 36. Global Precision Medicine Market Value, by Region ($Billion)
  • 37. Therapeutic Areas in Precision Medicine
  • 38. Global Precision Medicine Market, by Application, 2016 and 2026 ($Million)
  • 39. Global Precision Medicine Market Value, By Eco System Players ($Billion)
  • 40. Global Precision Medicine Market Value, by Region ($Billion)
  • 41. Types of Cancer
  • 42. Government Initiatives
  • 43. Cancer related Some Important Facts
  • 44. Oncology: Market Dynamics
  • 45. Global Precision Medicine Market Value, By Eco System Players ($Billion)
  • 46. Global Precision Medicine Market Value, by Region ($Billion)
  • 47. Global Precision Medicine Market Value, By Eco System Players ($Billion)
  • 48. Global Precision Medicine Market Value, by Region ($Billion)
  • 49. Global Precision Medicine Market Value, By Eco System Players ($Billion)
  • 50. Global Precision Medicine Market Value, by Region ($Billion)
  • 51. Global Precision Medicine Market Value, By Eco System Players ($Billion)
  • 52. Global Precision Medicine Market Value, by Region ($Billion)
  • 53. Global Precision Medicine Market Value, By Eco System Players ($Billion)
  • 54. Global Precision Medicine Market Value, by Region ($Billion)
  • 55. Global Precision Medicine Market Value, by Region ($Billion)
  • 56. North America Precision Medicine Market, By Region, 2015-2022 ($BILLION)
  • 57. North America Precision Medicine Market, By Ecosystem Players, 2015-2022 ($BILLION)
  • 58. North America Precision Medicine Market, By Therapeutic Applications, 2015-2022 ($BILLION)
  • 59. North America: Market Dynamics
  • 60. Key regulatory Bodies and Associations
  • 61. North America Precision Medicine Market, ($Billion)
  • 62. North America Precision Medicine Market, by Ecosystem Players, ($Billion)
  • 63. The U.S. Precision Medicine Market ($Billion)
  • 64. The U.S. Precision Medicine Market, by Ecosystem Players ($Billion)
  • 65. The U.S. Precision Medicine Market, by Technology ($Billion)
  • 66. The U.S. Precision Medicine Market, by Therapeutic Applications ($Billion)
  • 67. Objectives Of The Precision Medicine Initiative
  • 68. Canada Precision Medicine Market ($Billion)
  • 69. Canada: Market Dynamics
  • 70. Europe Precision Medicine Market, ($Billion)
  • 71. Europe Precision Medicine Market, by Region ($Billion)
  • 72. Europe Precision Medicine Market, by Ecosystem Players ($Billion)
  • 73. Europe Precision Medicine Market, by Technology ($Billion)
  • 74. Europe Precision Medicine Market, by Therapeutic Applications ($Billion)
  • 75. Europe: Market Dynamics
  • 76. Asia-Pacific (APAC) Precision Medicine Market, ($Billion)
  • 77. Asia Pacific (APAC) Precision Medicine Market, by Region ($Billion)
  • 78. Asia Pacific (APAC) Precision Medicine Market, by Ecosystem Players, ($Billion)
  • 79. Asia Pacific (APAC) Precision Medicine Market, by Technology ($Billion)
  • 80. Asia Pacific (APAC) Precision Medicine Market, by Therapeutic Applications ($Billion)
  • 81. Asia Pacific: Market Dynamics
  • 82. China: Market Dynamics
  • 83. India: Market Dynamics
  • 84. Rest of the World (RoW) Precision Medicine Market, ($Billion)
  • 85. Rest of the World (RoW)Precision Medicine Market, by Region ($Billion)
  • 86. Rest of the World (RoW) Precision Medicine Market, by Ecosystem Players, ($Billion)
  • 87. Rest of the World (RoW) Precision Medicine Market, by Technology ($Billion)
  • 88. Rest of the World (RoW) Precision Medicine Market, by Therapeutic Applications ($Billion)
  • 89. Middle East: Market Dynamics
  • 90. Examples of some of the programs helping in the Growth of Precision Medicine Market
  • 91. South America: Market Dynamics
  • 92. Africa: Market Dynamics
Back to Top